DrugPatentWatch Database Preview
Abbvie Company Profile
What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?
There are eighty-one US patents protecting ABBVIE drugs.
There are one thousand two hundred and eighty-four patent family members on ABBVIE drugs in sixty-six countries and one hundred and thirteen supplementary protection certificates in fourteen countries.
Summary for Abbvie
| International Patents: | 1284 |
| US Patents: | 81 |
| Tradenames: | 77 |
| Ingredients: | 64 |
| NDAs: | 89 |
| Drug Master File Entries: | 1 |
| Patent Litigation for Abbvie: | See patent lawsuits for Abbvie |
Drugs and US Patents for Abbvie
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Endocrine | LUPANETA PACK | leuprolide acetate; norethindrone acetate | INJECTABLE, TABLET;INTRAMUSCULAR, ORAL | 203696-002 | Dec 14, 2012 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Abbvie | ORETICYL 50 | deserpidine; hydrochlorothiazide | TABLET;ORAL | 012148-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Abbvie | MARINOL | dronabinol | CAPSULE;ORAL | 018651-001 | May 31, 1985 | AB | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | RX | Yes | Yes | 8,642,538 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Abbvie
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020517-001 | Dec 22, 1995 | 5,643,607 | ➤ Try a Free Trial |
| Abbvie Endocrine Inc | LUPRON DEPOT-PED | leuprolide acetate | INJECTABLE;INJECTION | 020263-007 | Aug 15, 2011 | 5,575,987 | ➤ Try a Free Trial |
| Abbvie | DEPAKOTE | divalproex sodium | CAPSULE, DELAYED REL PELLETS;ORAL | 019680-001 | Sep 12, 1989 | 5,212,326*PED | ➤ Try a Free Trial |
| Abbvie | CARTROL | carteolol hydrochloride | TABLET;ORAL | 019204-002 | Dec 28, 1988 | 3,910,924 | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial | ➤ Subscribe | 2009-08-04 |
| ➤ Subscribe | Extended-release Tablets | 250 mg | ➤ Subscribe | 2004-05-03 |
| ➤ Subscribe | Delayed-release Capsules | 45 mg | ➤ Subscribe | 2009-09-02 |
| ➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | Tablets | 400 mg and 600 mg | ➤ Subscribe | 2010-05-10 |
| ➤ Subscribe | Tablets | 2.5 mg/200 mg | ➤ Subscribe | 2006-02-24 |
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
| ➤ Subscribe | Tablets | 100 mg/25 mg | ➤ Subscribe | 2008-12-23 |
| ➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Capsules | 1 mcg and 2 mcg | ➤ Subscribe | 2008-10-14 |
| ➤ Subscribe | Oral Solution | 80 mg/20 mg per mL | ➤ Subscribe | 2014-06-19 |
| ➤ Subscribe | Gel Metered-dose Pump | 1% | ➤ Subscribe | 2008-12-19 |
| ➤ Subscribe | Extended-release Tablets | 2 mg/180 mg and 2 mg/240 mg | ➤ Subscribe | 2007-11-09 |
| ➤ Subscribe | Extended-release Tablets | 4 mg/ 240 mg | ➤ Subscribe | 2007-07-24 |
| ➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2009-08-12 |
| ➤ Subscribe | Extended-release Tablets | 500 mg | ➤ Subscribe | 2005-02-08 |
| ➤ Subscribe | Delayed-release Capsules | 135 mg | ➤ Subscribe | 2009-09-01 |
| ➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
| ➤ Subscribe | Extended-release Tablet | 500 mg | ➤ Subscribe | 2010-12-06 |
| ➤ Subscribe | Tablets | 5 mg/200 mg | ➤ Subscribe | 2005-05-27 |
| ➤ Subscribe | Gel | 1.62% | ➤ Subscribe | 2012-04-06 |
| ➤ Subscribe | Injection | 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials | ➤ Subscribe | 2008-11-28 |
| ➤ Subscribe | Gel | 1.62% (1.25 g and 2.5 g packets) | ➤ Subscribe | 2013-06-19 |
| ➤ Subscribe | Capsules | 4 mcg | ➤ Subscribe | 2008-08-25 |
| ➤ Subscribe | Tablets | 1 mg, 2 mg and 4 mg | ➤ Subscribe | 2004-10-04 |
| ➤ Subscribe | Extended-release Tablets | 1 mg/240 mg | ➤ Subscribe | 2008-02-20 |
Non-Orange Book US Patents for Abbvie
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,596,317 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it | ➤ Try a Free Trial |
| 7,659,405 | Polymorph of a pharmaceutical | ➤ Try a Free Trial |
| 9,023,878 | 2-iminobiotin formulations and uses thereof | ➤ Try a Free Trial |
| 7,927,627 | Nanoparticulate fibrate formulations | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Abbvie Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| New Zealand | 535368 | ➤ Try a Free Trial |
| Japan | 2006511541 | ➤ Try a Free Trial |
| Cyprus | 1115893 | ➤ Try a Free Trial |
| Russian Federation | 2286787 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Abbvie Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB07/011 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
| 2017000076 | Germany | ➤ Try a Free Trial | PRODUCT NAME: GLECAPREVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER ESTER DAVON; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| 99C0030 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508 |
| 2017000074 | Germany | ➤ Try a Free Trial | PRODUCT NAME: PIBRENTASVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
